- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Du Pont gets rights to infection tracer
Du Pont Merck Pharmaceuticalhas signed an agreement with Johnson & Johnson subsidiaryOrtho Pharmaceutical that gives Du Pont exclusive rights outsidethe Pacific Rim to Ortho's Macroscint agent for infection imaging.The agent is a human immunoglobulin
Du Pont Merck Pharmaceuticalhas signed an agreement with Johnson & Johnson subsidiaryOrtho Pharmaceutical that gives Du Pont exclusive rights outsidethe Pacific Rim to Ortho's Macroscint agent for infection imaging.The agent is a human immunoglobulin protein that is labeled withindium-111.
Du Pont of North Billerica, MA, claims that Macroscint is uniquein that it allows nuclear medicine physicians to conduct infectionimaging without the hazards and inconvenience associated withhandling blood from patients. Currently, infection imaging isconducted by drawing a patient's blood, labeling the white bloodcells with a radiotracer and injecting it back into the patient.With Macroscint, physicians inject the radiotracer into the patientlike any other radiopharmaceutical, according to Alan Carpenter,Du Pont's director of business development and planning.
Macroscint has completed phase-three clinical trials and DuPont is preparing a product license application (PLA) to the Foodand Drug Administration.
Du Pont will pay a licensing fee to Ortho for sales of Macroscintas part of the deal. In addition, Du Pont will acquire exclusiverights relating to basic research technology involving infectionimaging and technetium chemistry, according to Carpenter.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
